SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Amicus Therapeutics, Disclosing 7.4% Ownership
Beneficial Ownership Report (Schedule 13G Amendment)
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Amicus Therapeutics Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 22,765,804 shares of Amicus Therapeutics Inc. common stock.
- This represents 7.4% of the total outstanding common stock of Amicus Therapeutics Inc.
- BlackRock, Inc. holds sole voting power over 22,470,445 shares and sole dispositive power over 22,765,804 shares.
- The filing is an Amendment No. 10 to a Schedule 13G, indicating an update to a previously reported passive investment.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Amicus Therapeutics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While a 13G is a routine disclosure and doesn't contain performance data, a large, passive stake by a reputable institutional investor like BlackRock can be seen as a vote of confidence, albeit without active engagement in company control.
Positives
- The continued significant stake by a major institutional investor like BlackRock may signal confidence in Amicus Therapeutics Inc.'s long-term prospects.
- The filing indicates a passive investment strategy, suggesting BlackRock is not seeking to influence or change the control of the issuer.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Amicus Therapeutics Inc.'s future performance or strategic direction, as it is a beneficial ownership report.
Industry Context
This filing is a routine disclosure of institutional ownership in the biotechnology and pharmaceutical sector. Large institutional holdings like BlackRock's are common across publicly traded companies, reflecting diversified investment strategies. It does not provide specific insights into Amicus Therapeutics Inc.'s operational performance or competitive landscape, but rather confirms a significant, passive investment by a leading asset manager.
Stakeholder Impact
- Shareholders: The disclosure provides transparency regarding a significant institutional holder, which can influence market perception and liquidity. BlackRock's passive stance suggests no immediate impact on corporate strategy or governance from this specific filing.
- Company Management: Awareness of a large, passive institutional holder like BlackRock is important for investor relations, but this filing does not indicate any direct operational or strategic impact.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously issued Power of Attorney that was revoked by the new Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney granted by BlackRock, Inc. to its attorneys-in-fact. |
| 2025-03-31 | Date of the event which required the filing of this Schedule 13G Amendment No. 10. |
| 2025-04-23 | Date the Schedule 13G Amendment No. 10 was signed by BlackRock, Inc. |
Keywords
BlackRock, Amicus Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.